Apalutamide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Apalutamide and local guidelines before prescribing.
Antiandrogen
Mechanism
Androgen receptor inhibitor.
Uses
Non-metastatic and metastatic prostate cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Fatigue, rash, fractures, hypothyroidism, falls.
Interactions
CYP3A4 inducer reducing many drug levels.
Contraindications and cautions
Pregnancy
Monitoring
TFT, bone health
Pregnancy and breastfeeding
Not applicable
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Continue GnRH therapy.
More from the textbook: uses, cautions and other points
- Enzalutamide / apalutamide / darolutamide | Androgen receptor blockers; fatigue, falls, hypertension; interactions.
Oncology: Urology and Genital cancers - Enzalutamide, apalutamide, darolutamide - fatigue, falls, seizures (rare), hypertension.
Oncology: Principles - Plus a newer hormonal drug (abiraterone, enzalutamide, apalutamide or darolutamide), with or without docetaxel .
Oncology: Urology and Genital cancers
Where it is discussed in the book
- Oncology: Principles (1 mention)
- Oncology: Urology and Genital cancers (2 mentions)